Neuropeptide systems and schizophrenia

Amber L. LaCrosse, Michael Olive

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.

Original languageEnglish (US)
Pages (from-to)619-632
Number of pages14
JournalCNS and Neurological Disorders - Drug Targets
Volume12
Issue number5
DOIs
StatePublished - Aug 28 2013

Keywords

  • Antipsychotic
  • Cognitive deficits
  • Dopamine
  • Negative symptoms
  • Neuropeptide
  • Positive symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Neuropeptide systems and schizophrenia'. Together they form a unique fingerprint.

  • Cite this